[CAS NO. 29745-04-8] Norcantharidin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [29745-04-8]

Catalog

SLK-S3759

Brand

Selleck

CAS

29745-04-8

DESCRIPTION [29745-04-8]

Overview

MDL	MFCD00213361
Molecular Weight	168.15
Molecular Formula	C8H8O4
SMILES	O=C1[C@]2([C@]([C@H]3O[C@@H]2CC3)(C(=O)O1)[H])[H]

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	5.9471 mL	29.7354 mL	59.4707 mL
5 mM	1.1894 mL	5.9471 mL	11.8941 mL
10 mM	0.5947 mL	2.9735 mL	5.9471 mL
50 mM	0.1189 mL	0.5947 mL	1.1894 mL

Description

Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for in human colon cancers.

Targets

c-Met ^[1]

EGFR ^[1]

In vitro

Norcantharidin (NCTD) induces cell cycle arrest at G2/M phase in HCT116 and HT29 cells. NCTD suppresses not only the expression of the total EGFR and the phosphorylated EGFR but also the expression of the total c-Met and the phosphorylated c-Met in colon cancer cells. Norcantharidin (NCTD) is an inhibitor of protein phosphatase types 1, 2A and 2B, arrests the cell cycle at G2/M phase in K562 human myeloid leukemia cells, and inhibits DNA synthesis in HL-60 cells.

In vivo

Norcantharidin (NCTD) inhibits the growth of the xenografted tumors in a dose- and time-dependent manner. Tumor volume decreases with an increased tumor inhibitory rate in the NTCD group compared with the control group. The apoptosis rate increases along with a decreased percentage of cells in S phase in the NTCD group compared with the control group. The morphological changes of apoptosis such as nuclear shrinkage, chromatin aggregation, chromosome condensation, and typical apoptosis bodies in the xenografted tumor cells induced by NCTD are observed. The expression of cyclin-D1, Bcl-2 and survivin proteins/mRNAs decrease significantly, with increased expression of p27 and Bax proteins/mRNAs in the NCTD group compared with the control group. NCTD is reported clinically as an anti-tumor drug against hepatoma, esophageal and gastric carcinoma, and leucopenia.

References

[1] Qiu P, et al. BMC Cancer. 2017, 17(1):55.
[2] Fan YZ, et al. Hepatobiliary Pancreat Dis Int. 2010, 9(4):414-22.

Synonyms

4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-, (3aR,4S,7R,7aS)-rel-

7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride, exo-

4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-, (3aα,4β,7β,7aα)-

rel-(3aR,4S,7R,7aS)-Hexahydro-4,7-epoxyisobenzofuran-1,3-dione

7-Oxabicyclo[2.2.1]heptane-exo-cis-2,3-dicarboxylic anhydride

Norcantharidin

NSC 59023

(3aR,4S,7R,7aS)-rel-Hexahydro-4,7-epoxyisobenzofuran-1,3-dione

Isocantharidin

Demethylcantharidin

exo-7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride